Evidence map›Paper›PMID 38001577›Full record

ArticleCancers2023

Adjuvant Immunotherapy in Curative Intent Esophageal Cancer Resection Patients: Real-World Experience within an Integrated Health System.

Hyunjee V Kwak, Kian C Banks, Yun-Yi Hung, Nathan J Alcasid, Cynthia J Susai, Ashish Patel, Simon Ashiku, Jeffrey B Velotta

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hyunjee V KwakDepartment of Surgery, University of California, San Francisco-East Bay, 1411 E 31st Street, QIC 22134, Oakland, CA 94602, USA.ORCID 0000-0002-3636-2172
Kian C BanksDepartment of Surgery, University of California, San Francisco-East Bay, 1411 E 31st Street, QIC 22134, Oakland, CA 94602, USA.ORCID 0000-0001-9623-8627
Yun-Yi HungBiostatistical Consulting Unit, Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA.
Nathan J AlcasidDepartment of Surgery, University of California, San Francisco-East Bay, 1411 E 31st Street, QIC 22134, Oakland, CA 94602, USA.
Cynthia J SusaiDepartment of Surgery, University of California, San Francisco-East Bay, 1411 E 31st Street, QIC 22134, Oakland, CA 94602, USA.
Ashish PatelDivision of Thoracic Surgery, Department of Surgery, Kaiser Permanente Northern California, 3600 Broadway, Oakland, CA 94612, USA.
Simon AshikuDivision of Thoracic Surgery, Department of Surgery, Kaiser Permanente Northern California, 3600 Broadway, Oakland, CA 94612, USA.
Jeffrey B VelottaDivision of Thoracic Surgery, Department of Surgery, Kaiser Permanente Northern California, 3600 Broadway, Oakland, CA 94612, USA.ORCID 0000-0002-1405-8487
Kaiser Permanente · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdjuvant immunotherapy has been shown in clinical trials to prolong the survival of patients with esophageal cancer. We report our initial experience with immunotherapy within an integrated health system.

methodsA retrospective cohort study was performed reviewing patients undergoing minimally invasive esophagectomy at our institution between 2017 and 2021. The immunotherapy cohort was assessed for completion of treatment, adverse effects, and disease progression, with emphasis on patients who received surgery in 2021 and their eligibility to receive nivolumab.

resultsThere were 39 patients who received immunotherapy and 137 patients who did not. In logistic regression, immunotherapy was not found to have a statistically significant impact on 1-year overall survival after adjusting for age and receipt of adjuvant chemoradiation. Only seven patients out of 39 who received immunotherapy successfully completed treatment (18%), with the majority failing therapy due to disease progression or side effects. Of the 17 patients eligible for nivolumab, 13 patients received it (76.4%), and three patients completed a full course of treatment.

conclusionsDespite promising findings of adjuvant immunotherapy improving the survival of patients with esophageal cancer, real-life practice varies greatly from clinical trials. We found that the majority of patients were unable to complete immunotherapy regimens with no improvement in overall 1-year survival.

Indexed as

esophageal cancerimmunotherapynivolumab

Identifiers

PMID38001577
PMCPMC10669669
OpenAlexW4388465088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.